Framingham score
Reading File
Finding Sources
Searching PubMed
"Framingham Risk Score"
Searching the Web
Framingham Risk Score calculator variables 10 year cardiovascular risk official
Framingham score is a cardiovascular risk calculator that estimates a person’s risk of developing cardiovascular disease over the next 10 years.
Common versions predict:
- Coronary heart disease: myocardial infarction or coronary death
- General cardiovascular disease: coronary disease, stroke, heart failure, peripheral arterial disease, etc.
- Other outcomes such as atrial fibrillation
For the classic 10-year coronary risk score, the main inputs are:
- Age and sex
- Total cholesterol
- HDL cholesterol
- Systolic blood pressure
- Whether blood pressure is treated
- Current smoking status
- Diabetes, in some versions
The Framingham Heart Study provides the risk functions and point tables, including the traditional “hard coronary heart disease” score. Framingham risk functions
If you want me to calculate it, send:
- Age
- Sex
- Total cholesterol and HDL, with units
- Systolic BP
- On BP medication: yes/no
- Current smoker: yes/no
- Diabetes: yes/no
- Whether you want coronary-heart-disease risk or general CVD risk.
A limitation is that Framingham was derived from a specific US cohort, so it may overestimate or underestimate risk in some populations. A 2024 systematic review found important shortcomings in how its external validation has been reported (PMID: 39269949).
Explain Framingham versus ASCVD risk scoring
Reading File
Finding Sources
Searching PubMed
ASCVD Framingham risk prediction
Searching the Web
2018 ACC AHA guideline ASCVD risk estimator Pooled Cohort Equations thresholds 5 7.5 20
“ASCVD risk score” usually refers to the ACC/AHA Pooled Cohort Equations (PCE). Both it and the Framingham Risk Score (FRS) estimate future cardiovascular risk, but they differ in the events they predict and their main clinical use.
| Feature | Framingham Risk Score | ASCVD risk score, PCE |
|---|---|---|
| Origin | Framingham Heart Study cohort | Multiple US cohorts pooled by ACC/AHA |
| Typical prediction horizon | 10 years | 10 years, with lifetime-risk tools also available |
| Main outcomes | Varies by version: “hard CHD” or broader general CVD | First “hard ASCVD” event: nonfatal MI, coronary death, fatal/nonfatal stroke |
| Variables | Age, sex, total cholesterol, HDL-C, systolic BP, BP treatment, smoking; some versions include diabetes or BMI | Age, sex, total cholesterol, HDL-C, systolic BP, antihypertensive treatment, diabetes, smoking; traditional PCE also uses race-specific equations |
| Main historical role | General cardiovascular risk assessment and epidemiology | US primary-prevention decisions, especially lipid-lowering treatment discussions |
| Typical population | Most classic versions: adults about 30-74 years, depending on model | Usually adults 40-79 years without established ASCVD |
The key difference is the outcome
Framingham is a family of scores, not one single score:
- Hard CHD Framingham predicts myocardial infarction or coronary death.
- General CVD Framingham can include coronary events, stroke/TIA, heart failure, and peripheral arterial disease.
- Other Framingham equations estimate risks for atrial fibrillation, heart failure, hypertension, and more.
By contrast, the traditional ASCVD PCE has a more standardized endpoint: MI, coronary death, or stroke. It is therefore more directly aligned with atherosclerotic events and preventive lipid treatment.
How the traditional ASCVD score is interpreted
For adults aged 40-75 without diabetes, established ASCVD, or LDL-C ≥190 mg/dL, traditional ACC/AHA practice has categorized 10-year PCE risk as:
- Low: <5%
- Borderline: 5% to <7.5%
- Intermediate: 7.5% to <20%
- High: ≥20%
At borderline or intermediate risk, clinicians consider factors not fully captured by the equation, for example premature family history of ASCVD, chronic kidney disease, inflammatory disease, elevated lipoprotein(a), elevated apoB, persistent high triglycerides, or a coronary artery calcium score. The ACC summary of risk-enhancing factors describes this approach.
Which score should be used?
- For a US-based cholesterol or statin-prevention discussion: the traditional answer has been the ACC/AHA ASCVD PCE, rather than Framingham. The ACC ASCVD estimator was designed for this primary-prevention context.
- For broader cardiovascular prognosis or settings outside that guideline context: a Framingham general-CVD score may be useful, provided it has been validated for the person’s population.
- Do not use either as the sole decision-maker. Both can miscalibrate in populations differing from their derivation cohorts, including some ethnic groups and people with HIV, chronic inflammatory disease, or significant social/clinical risk factors not in the model.
Important 2026 update
If you mean current US lipid guidance, this distinction is changing. The 2026 ACC/AHA dyslipidemia guideline now recommends the newer PREVENT-ASCVD equations rather than the older PCE for primary prevention in adults aged 30-79. PREVENT was designed to update risk prediction and includes kidney function and other contemporary predictors; it does not use race as a predictor. The ACC guideline announcement summarizes the new risk categories and role of PREVENT.
So, in short:
Framingham is an older, flexible set of cardiovascular prediction tools.
ASCVD PCE is a more specific US guideline-oriented 10-year MI/stroke risk tool.
PREVENT-ASCVD is the newer US approach replacing PCE in current 2026 lipid guidance.
A recent systematic review also identified weaknesses in the reporting of external validation studies for a Framingham coronary risk rule, reinforcing that calibration in the patient’s own population matters (PMID: 39269949).
SCORE 2
Reading File
Finding Sources
Searching PubMed
SCORE2 cardiovascular risk prediction
Searching the Web
ESC SCORE2 SCORE2-OP age range predictors risk categories official guideline
SCORE2 and SCORE2-OP
SCORE2 is the European Society of Cardiology (ESC) cardiovascular risk calculator for primary prevention. It estimates an individual’s 10-year risk of a first fatal or nonfatal cardiovascular event:
- Nonfatal myocardial infarction
- Coronary death
- Nonfatal or fatal ischaemic stroke
It replaced the older SCORE model, which predicted fatal cardiovascular disease only. Because SCORE2 includes nonfatal events, its percentages are higher and should not be interpreted using old SCORE thresholds.
Who is it for?
| Tool | Intended population |
|---|---|
| SCORE2 | Apparently healthy adults aged 40-69 years |
| SCORE2-OP | Apparently healthy adults aged 70 years or older |
They are intended for people without established ASCVD and not already automatically classified as high or very-high risk.
Do not use SCORE2 as the main risk tool for people with:
- Known ASCVD, such as prior MI, stroke, peripheral arterial disease, or coronary revascularization
- Diabetes
- Chronic kidney disease
- Familial hypercholesterolaemia or very high LDL-C
- Rare genetic lipid or blood-pressure disorders
- Current lipid-lowering treatment, when the goal is to estimate untreated baseline risk
These conditions require direct guideline-based risk classification and management rather than relying on a calculated percentage.
Inputs
SCORE2 uses:
- Age
- Sex
- Smoking status
- Systolic blood pressure
- Total cholesterol and HDL-C, effectively incorporating non-HDL cholesterol
SCORE2-OP uses these factors and additionally includes diabetes as a predictor.
The model is calibrated to four European cardiovascular-mortality risk regions: low, moderate, high, and very high. Therefore, the country/region selected matters. ESC overview of SCORE2
Risk interpretation
Risk cut-offs should be interpreted in relation to age, because a given 10-year percentage has different implications at 45 versus 68 years.
Common ESC 2021 age-specific thresholds were:
| Age | Low to moderate | High | Very high |
|---|---|---|---|
| <50 years | <2.5% | 2.5% to <7.5% | ≥7.5% |
| 50-69 years | <5% | 5% to <10% | ≥10% |
| ≥70 years, SCORE2-OP | <7.5% | 7.5% to <15% | ≥15% |
The newer 2025 ESC/EAS focused update also expresses general SCORE2/SCORE2-OP categories as low <2%, moderate 2% to <10%, high 10% to <20%, and very high ≥20%, while emphasizing that treatment decisions should incorporate age, baseline LDL-C, comorbidity, risk modifiers, expected benefit, and patient preference. 2025 ESC/EAS update
SCORE2 versus Framingham versus ASCVD PCE
| Feature | SCORE2 | Framingham | Traditional US ASCVD PCE |
|---|---|---|---|
| Main setting | Europe | Broad international/historical use | United States |
| Event predicted | Fatal or nonfatal MI, stroke, or CV death | Varies: CHD or broader CVD, depending on version | Nonfatal MI, coronary death, fatal/nonfatal stroke |
| Population calibration | European country risk regions | Original US Framingham cohort | US cohorts |
| Age range | 40-69; SCORE2-OP at ≥70 | Depends on the model | Usually 40-79 |
| Main role | ESC primary prevention | General CVD-risk estimation | ACC/AHA primary prevention and lipid decisions |
Practical rule: use the calculator recommended for the guideline and population you are working in. For European ESC prevention, use SCORE2/SCORE2-OP rather than Framingham or the US ASCVD PCE.
MACE
Reading File
Finding Sources
Searching PubMed
"major adverse cardiovascular events"
Searching the Web
major adverse cardiovascular events MACE definition composite endpoint variability
MACE means Major Adverse Cardiovascular Events.
It is a composite clinical endpoint used in cardiovascular studies to combine serious events into one outcome measure.
Most common definition: 3-point MACE
- Cardiovascular death
- Nonfatal myocardial infarction (heart attack)
- Nonfatal stroke
For example, the SELECT trial defined MACE as the first occurrence of cardiovascular death, nonfatal MI, or nonfatal stroke. ACC trial summary
Important caveat
MACE is not standardized. Always inspect the study protocol's endpoint definition. Some trials use:
- 4-point MACE: 3-point MACE plus hospitalization for unstable angina
- 5-point MACE: may also add coronary revascularization or heart-failure hospitalization
- Other trial-specific composites, sometimes including urgent revascularization or all-cause death
So, a statement such as “Drug X reduced MACE” does not automatically mean it reduced all individual components. Check:
- Which events were included
- The individual event results, especially CV death
- Absolute event rates and absolute risk reduction
- Follow-up duration and study population
MACE versus ASCVD risk: ASCVD risk calculators predict an individual's chance of a future atherosclerotic event; MACE is usually a research outcome used to compare event rates between treatment groups.
MINOCA
Reading File
Finding Sources
Searching PubMed
MINOCA diagnosis management
Searching the Web
MINOCA definition diagnostic workup cardiac MRI coronary imaging guideline
MINOCA
MINOCA means Myocardial Infarction with Non-Obstructive Coronary Arteries.
It describes a patient who has a true acute myocardial infarction but whose coronary angiogram shows no obstructive stenosis, conventionally no lesion of 50% or greater in a major epicardial coronary artery.
It is a working diagnosis, not the final diagnosis
MINOCA is not one disease. After angiography, further testing must determine the actual mechanism. It represents roughly 6% to 10% of acute MI presentations and is relatively more common in women and younger patients. Braunwald’s Heart Disease describes it as a heterogeneous syndrome requiring further evaluation to identify a cause and exclude noncoronary injury. Braunwald’s Heart Disease, 2 Vol Set, section “Myocardial Infarction with Nonobstructive Coronary Artery Disease.”
Diagnostic requirements
All three should be present:
- Acute MI, based on the Universal Definition:
- Rise and/or fall in cardiac troponin with at least one value above the 99th percentile, plus clinical evidence of acute myocardial ischemia, such as ischemic symptoms, ECG change, imaging evidence, or coronary thrombus.
- Non-obstructive coronaries on angiography, usually <50% stenosis.
- No obvious alternative explanation at the time of angiography, such as sepsis-related myocardial injury.
Important causes
Coronary causes
- Plaque rupture, plaque erosion, or transient thrombosis not apparent on routine angiography
- Coronary vasospasm
- Coronary microvascular dysfunction
- Spontaneous coronary artery dissection (SCAD)
- Coronary embolism or thrombosis
- Supply-demand mismatch, for example severe anemia, tachyarrhythmia, or hypoxemia, when it fulfills MI criteria
Conditions that can mimic MINOCA but are not ischemic MI
- Myocarditis
- Takotsubo syndrome
- Pulmonary embolism
- Other causes of acute myocardial injury
Evaluation after angiography
The work-up is mechanism-based:
- Review the angiogram carefully.
- Consider OCT or IVUS during angiography to detect plaque disruption or SCAD missed by conventional angiography.
- Perform cardiac MRI, ideally early, to distinguish infarction from myocarditis or Takotsubo syndrome and characterize the pattern of myocardial injury.
- Consider coronary functional testing, including vasospasm provocation, when spasm or microvascular dysfunction is suspected.
- Investigate embolic sources when appropriate, such as atrial fibrillation, ventricular thrombus, valve disease, or thrombophilia.
The ESC MINOCA review emphasizes cardiac MRI, intracoronary imaging, and coronary functional testing as complementary tools.
Treatment
Treatment is not identical for every patient and should target the identified mechanism:
| Mechanism | Typical direction of treatment |
|---|---|
| Plaque disruption | Secondary prevention similar to atherosclerotic MI: statin, antiplatelet therapy, ACE inhibitor/ARB, beta-blocker when indicated |
| Coronary vasospasm | Calcium-channel blocker, often nitrates; smoking cessation |
| SCAD | Usually conservative management unless ongoing ischemia/instability; avoid unnecessary PCI |
| Embolic MI | Treat source, possibly anticoagulation depending on cause |
| Myocarditis or Takotsubo | These are not MINOCA once identified; manage according to the specific diagnosis |
Key message: do not dismiss MINOCA as a “false heart attack.” It has meaningful risks of recurrent cardiovascular events and requires a structured evaluation and cause-specific prevention. Recent invasive-assessment evidence supports the value of identifying hidden pathology with intracoronary imaging (PMID: 39689931).
Peripheral arterial disease and Ankke brachial index
Reading File
Finding Sources
Searching PubMed
peripheral artery disease ankle brachial index
Searching the Web
2024 ACC AHA peripheral artery disease guideline ankle brachial index interpretation exercise toe brachial index
Searching Images
diagram showing ankle brachial index measurement dorsalis pedis posterior tibial brachial artery blood pressure cuffs Doppler
Peripheral Arterial Disease and the Ankle-Brachial Index
Peripheral arterial disease
Peripheral arterial disease (PAD) is atherosclerotic narrowing or occlusion of arteries outside the heart and brain, most often in the lower limbs. It reduces blood flow to skeletal muscle and, in severe cases, threatens limb viability.
Risk factors
- Smoking
- Diabetes mellitus
- Older age
- Hypertension
- Dyslipidaemia
- Chronic kidney disease
- Established coronary or cerebrovascular disease
Clinical presentations
- Intermittent claudication: reproducible calf, thigh, or buttock pain on walking that resolves within minutes of rest.
- Atypical leg symptoms: fatigue, heaviness, or discomfort that may not be classic claudication.
- Chronic limb-threatening ischaemia: rest pain, nonhealing ulcer, or gangrene.
- Many patients are asymptomatic but still have increased risk of MI, stroke, and cardiovascular death.
Examination
- Diminished/absent peripheral pulses
- Bruits
- Cool, pale foot, delayed capillary refill
- Shiny skin, hair loss, thickened nails, muscle wasting
- Ulcers, typically painful and distal, with sharply demarcated edges in severe ischaemia
Ankle-brachial index (ABI)
The ABI is a simple, non-invasive bedside test for lower-extremity PAD.
Formula
[
\text{ABI for each leg} =
\frac{\text{highest ankle systolic pressure in that leg}}{\text{highest brachial systolic pressure in either arm}}
]
At the ankle, use a Doppler probe to measure systolic pressure in both:
- Dorsalis pedis artery
- Posterior tibial artery
Use the higher of the two ankle pressures. Then divide by the higher arm systolic pressure.
Example
- Right dorsalis pedis pressure: 100 mmHg
- Right posterior tibial pressure: 110 mmHg
- Highest brachial pressure: 140 mmHg
[
\text{Right ABI} = \frac{110}{140} = 0.79
]
This is abnormal and supports PAD in the right leg.
Interpretation
| ABI | Interpretation |
|---|---|
| 1.00-1.40 | Normal |
| 0.91-0.99 | Borderline |
| ≤0.90 | Diagnostic of PAD |
| 0.41-0.90 | Mild to moderate PAD |
| ≤0.40 | Severe PAD, often associated with severe ischaemia |
| >1.40 | Noncompressible, calcified arteries, so ABI is unreliable |
A chronic PAD ABI is generally <0.90, while <0.40 suggests severe disease; values above about 1.3-1.4 commonly reflect noncompressible arteries. Tintinalli's Emergency Medicine: A Comprehensive Study, section “Acute Versus Chronic Arterial Disease.”
Important limitations
An ABI may be falsely normal or high in people with arterial medial calcification, particularly those with:
- Diabetes
- Advanced chronic kidney disease
- Older age
If ABI is >1.40 or noncompressible, use a toe-brachial index (TBI) because toe arteries are less prone to calcification.
[
\text{TBI} =
\frac{\text{toe systolic pressure}}{\text{highest brachial systolic pressure}}
]
A TBI ≤0.70 is generally abnormal.
If exertional symptoms strongly suggest PAD but resting ABI is normal or borderline, perform an exercise ABI. A fall in ABI after exercise supports flow-limiting PAD.
The 2024 ACC/AHA PAD guideline recommends resting ABI for patients with history or examination findings suggestive of PAD, and recommends toe pressures/TBI with waveforms as additional testing when chronic limb-threatening ischaemia is suspected. 2024 ACC/AHA PAD guidance
Management principles
For every patient with PAD
- Complete smoking cessation
- Supervised exercise therapy or structured walking program
- Statin therapy
- Control blood pressure and diabetes
- Foot care, particularly in diabetes
- Antiplatelet therapy when indicated for symptomatic PAD
Revascularization
Endovascular or surgical revascularization is considered for:
- Claudication that remains functionally limiting despite guideline-directed medical therapy and structured exercise
- Chronic limb-threatening ischaemia, such as rest pain, tissue loss, or gangrene
- Acute limb-threatening ischaemia, which needs urgent vascular assessment
Clinical pearl: An abnormal ABI identifies not only leg arterial disease but also a high overall atherosclerotic risk. PAD should prompt active cardiovascular risk reduction, not treatment of leg symptoms alone.
This is a shared conversation. Sign in to Orris to start your own chat.